[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Primus Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":132},{"warningLetters":4,"total":131},[5,31,50,73,91,112],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1658,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-01-09T14:20:00Z\">01\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-02T05:00:00Z\">01\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-lab-llc-667057-01022024\">Prime Lab LLC\u003C\u002Fa>","Office of Pharmaceutical Quality","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Fernando Rodriguez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Prime Lab LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Sabanetas Industrial Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Building M, Solar 18, Local 2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ponce\u003C\u002Fspan> \u003Cspan>00716\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:gpagan@primjanitorial.com\"> gpagan@primjanitorial.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 2, 2024\u003C\u002Fp>\n\n\u003Cp>Case # 667057\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Rodriguez:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Prime Lab LLC, FEI 3017199840, at Sabanetas Industrial Park Building M, Solar 18, Local 2, Ponce, from July 31 to August 4, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your August 24, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) antibacterial hand soap and hand sanitizer drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each component lot used in the manufacture of your OTC drug products. You also stated that you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to developing procedures for the receipt of incoming raw materials. You also state that you will identify an external laboratory to test raw materials. Your response is inadequate. You failed to provide sufficient details regarding how you will ensure at least one identity test for each lot of each shipment of incoming raw materials is performed and how you will validate your suppliers’ COA. You also do not address how you will assess the quality of your components used in your distributed drug products that are within expiry.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with diethylene glycol (DEG) or ethylene glycol (EG) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>You also manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the incoming components and finished drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate equipment cleaning and maintenance procedures. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You lacked adequate written procedures describing your cleaning process and appropriate documentation of your equipment cleaning. Your production equipment cleaning is performed by rinsing with water and using rags for an unspecified length of time.\u003C\u002Fli>\n\t\u003Cli>You manufactured drug products using the same equipment that you use to manufacture non-drug products, including industrial detergents and disinfectants such as a multi-purpose grease remover. This disinfectant product contains the ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> which may be toxic in contact with skin and may cause an allergic skin reaction. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture toxic industrial-grade products due to the risk of cross-contamination.\u003C\u002Fli>\n\t\u003Cli>You did not conduct routine calibration and preventative maintenance of your equipment, and that maintenance is only performed when repairs are needed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you commit to developing procedures for your cleaning process and maintaining cleaning records. You also state that you will review the existing mixing tank and accessories to determine if you need to requalify or add a new mixing tank. Your response is inadequate. You failed to retrospectively assess your finished drug products that are currently on the market and within expiry for potential risk of cross contamination with toxic industrial-grade products. Further, your response did not provide sufficient details of your revised cleaning and maintenance procedures.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\u003C\u002Fli>\n\t\u003Cli>If you intend to continue manufacturing both pharmaceutical and nonpharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>Provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning procedures, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Appropriate laboratory determination of satisfactory conformance to final specifications for your finished drug products (21 CFR 211.165(a).\u003C\u002Fli>\n\t\u003Cli>Adequate design and procedures for production and process controls for drug products and for maintenance and monitoring of your water system used to manufacture drug products, including a lack of investigation into out of limit microbiology test results during the installation of your water system (21 CFR 211.100(a) and 211.192)).\u003C\u002Fli>\n\t\u003Cli>Drug products bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state that you are in the process of improving your quality management system and creating a QU. You also state that you will use an external laboratory to determine appropriate expiration dates for your drug products. Your response is inadequate. You do not adequately describe how your QU plans to improve its oversight of manufacturing quality. You also failed to assess the impact of insufficient QU oversight on risk to product quality.\u003C\u002Fp>\n\n\u003Cp>Additionally, in your response, you do not assess the need for improvements to your water system, including maintenance and monitoring. In addition, you did not provide adequate details about your finished drug product release testing and specifications, or if you will perform microbiology testing of your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; &nbsp; o Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specifications results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures.\u003C\u002Fli>\n\t\u003Cli>Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. · A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of all drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Mr. Rivero by email or by phone at (954) 759-7718.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tamala Bogan\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>_____________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Fernando Rodriguez\n\nRecipient Title\n\nPresident and CEO\n\nPrime Lab LLC\n\nSabanetas Industrial Park\n\nBuilding M, Solar 18, Local 2\n\nPonce 00716\n\nPuerto Rico\n\ngpagan@primjanitorial.com\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nJanuary 2, 2024\n\nCase # 667057\n\nDear Mr. Rodriguez:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Prime Lab LLC, FEI 3017199840, at Sabanetas Industrial Park Building M, Solar 18, Local 2, Ponce, from July 31 to August 4, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your August 24, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) antibacterial hand soap and hand sanitizer drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each component lot used in the manufacture of your OTC drug products. You also stated that you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\n\nIn your response, you commit to developing procedures for the receipt of incoming raw materials. You also state that you will identify an external laboratory to test raw materials. Your response is inadequate. You failed to provide sufficient details regarding how you will ensure at least one identity test for each lot of each shipment of incoming raw materials is performed and how you will validate your suppliers’ COA. You also do not address how you will assess the quality of your components used in your distributed drug products that are within expiry.\n\nThe use of ingredients contaminated with diethylene glycol (DEG) or ethylene glycol (EG) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nYou also manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the incoming components and finished drug products you manufacture.\n\n2. Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm lacked adequate equipment cleaning and maintenance procedures. For example,\n\nYou lacked adequate written procedures describing your cleaning process and appropriate documentation of your equipment cleaning. Your production equipment cleaning is performed by rinsing with water and using rags for an unspecified length of time.\n\nYou manufactured drug products using the same equipment that you use to manufacture non-drug products, including industrial detergents and disinfectants such as a multi-purpose grease remover. This disinfectant product contains the ingredient (b)(4) which may be toxic in contact with skin and may cause an allergic skin reaction. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture toxic industrial-grade products due to the risk of cross-contamination.\n\nYou did not conduct routine calibration and preventative maintenance of your equipment, and that maintenance is only performed when repairs are needed.\n\nIn your response, you commit to developing procedures for your cleaning process and maintaining cleaning records. You also state that you will review the existing mixing tank and accessories to determine if you need to requalify or add a new mixing tank. Your response is inadequate. You failed to retrospectively assess your finished drug products that are currently on the market and within expiry for potential risk of cross contamination with toxic industrial-grade products. Further, your response did not provide sufficient details of your revised cleaning and maintenance procedures.\n\nIn response to this letter provide:\n\nConfirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\n\nIf you intend to continue manufacturing both pharmaceutical and nonpharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nProvide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\nAppropriate improvements to your cleaning procedures, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n3. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\n\nYour quality unit (QU) failed to provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAppropriate laboratory determination of satisfactory conformance to final specifications for your finished drug products (21 CFR 211.165(a).\n\nAdequate design and procedures for production and process controls for drug products and for maintenance and monitoring of your water system used to manufacture drug products, including a lack of investigation into out of limit microbiology test results during the installation of your water system (21 CFR 211.100(a) and 211.192)).\n\nDrug products bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\n\nIn your response, you state that you are in the process of improving your quality management system and creating a QU. You also state that you will use an external laboratory to determine appropriate expiration dates for your drug products. Your response is inadequate. You do not adequately describe how your QU plans to improve its oversight of manufacturing quality. You also failed to assess the impact of insufficient QU oversight on risk to product quality.\n\nAdditionally, in your response, you do not assess the need for improvements to your water system, including maintenance and monitoring. In addition, you did not provide adequate details about your finished drug product release testing and specifications, or if you will perform microbiology testing of your finished drug products.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specifications results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures.\n\nDescribe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. · A timeline for performing appropriate PPQ for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of all drugs at this facility. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations.\n\nYou are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov.\n\nIf you have questions regarding any issues in this letter, please contact Mr. Rivero by email or by phone at (954) 759-7718.\n\nSincerely,\n\n\u002FS\u002F\n\nTamala Bogan\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision II\n\n_____________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Prime Lab LLC","prime-lab-llc-667057-01022024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-lab-llc-667057-01022024","2026-10-26T08:09:44.059838+00:00","Warning Letter","Issued","2024-01-09","667057","Drugs","Mr. Fernando Rodriguez","2026-08-20T00:23:25.415+00:00","Via Email","2024-01-02",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":48,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},241,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026\">Prime Sciences\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs Sold Over the Internet","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14500 N. Northsight Blvd, STE 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@prime-sciences.com\"> info@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prime-sciences.com\"> support@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 721805\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prime Sciences:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cagrilintide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\u003C\u002Fp>\u003Cul>\u003Cli>“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\u003C\u002Fli>\u003Cli>“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-R (10MG) (identified as Retatrutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\u003C\u002Fp>\u003Cul>\u003Cli>“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\u003C\u002Fli>\u003Cli>“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-S (10MG) (identified as Semaglutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic – Weight Loss Supplement.”\u003C\u002Fli>\u003Cli>“Semaglutide peptide therapy benefits include:\u003Cbr>o Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\u003Cbr>o Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\u003Cbr>o Reduces blood sugar levels to promote weight loss”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-T (10MG) (identified as Tirzepatide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\u003C\u002Fp>\u003Cul>\u003Cli>“Tirzepatide therapy benefits include:\u003Cbr>o A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\u003Cbr>o Stimulates the production of insulin to lower blood sugar\u003Cbr>o Reduces appetite by slowing the time it takes the stomach to empty”\u003C\u002Fli>\u003Cli>“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MAZDUTIDE (10MG)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide peptide therapy benefits include:\u003Cbr>o Weight Management\u003Cbr>􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\u003C\u002Fli>\u003Cli>“Improved metabolic health\u003Cbr>o Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\u003Cbr>o Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\u003Cbr>o Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BAC water\u003C\u002Fu>\u003Cbr>Your firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\u003C\u002Fp>\u003Cp>Your Prime Sciences products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPrime Sciences\n\n14500 N. Northsight Blvd, STE 100\n\nScottsdale, AZ 85260\n\nUnited States\n\ninfo@prime-sciences.com\n\nsupport@prime-sciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 721805\nPrime Sciences:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nDespite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\nExamples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nCagrilintide\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\n“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\n“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-R (10MG) (identified as Retatrutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\n“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\n“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\nGLP1-S (10MG) (identified as Semaglutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\n“Ozempic – Weight Loss Supplement.”\n“Semaglutide peptide therapy benefits include:\no Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\no Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\no Reduces blood sugar levels to promote weight loss”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-T (10MG) (identified as Tirzepatide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\n“Tirzepatide therapy benefits include:\no A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\no Stimulates the production of insulin to lower blood sugar\no Reduces appetite by slowing the time it takes the stomach to empty”\n“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\nMAZDUTIDE (10MG)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\n“Mazdutide peptide therapy benefits include:\no Weight Management\n􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\n“Improved metabolic health\no Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\no Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\no Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\nBAC water\nYour firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\nYour Prime Sciences products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Sciences","prime-sciences-721805-03312026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026","2026-10-26T08:09:44.094362+00:00","2026-04-07","721805","2026-08-19T04:49:30.204+00:00","2026-03-31",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":68,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},2171,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-02-21T05:00:00Z\">02\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprimal-pet-foods-inc-645467-02212023\">Primal Pet Foods, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V ","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy Simonds\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Primal Pet Foods, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>535 Watt Drive, Suite B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fairfield\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94534-1790\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 21, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL 645467\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Simonds:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 535 Watt Drive, Suite B, Fairfield, CA 94534-1790 from July 14 through October 11, 2022. This inspection was conducted in response to a Class 1 recall initiated on July 6, 2022, of Raw Frozen Primal Patties for Dogs Beef Formula, lot number W10068709, due to the presence of \u003Cem>Listeria monocytogenes\u003C\u002Fem> detected in an FDA surveillance sample.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed evidence of significant violations of FDA’s Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals regulation, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Also, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>You may find the FD&amp;C Act and FDA’s regulations through links in FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, you were issued a Form FDA-483, Inspectional Observations. We received your written response dated November 1, 2022. We have reviewed your response and we discuss your corrective actions below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your animal food facility is subject to the Hazard Analysis and Risk-Based Preventive Controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During our inspection of your facility, the FDA Investigator observed evidence of significant violations of these requirements including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. You did not identify and implement preventive controls to provide assurances that anyhazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm manufactures raw frozen and raw freeze-dried pet food and treats for dogs and cats. Your hazard analysis determined pathogens (\u003Cem>Salmonella\u003C\u002Fem> spp., \u003Cem>Listeria monocytogenes\u003C\u002Fem>, and E. coli O157:H7) are a hazard requiring a preventive control at the following steps: “Inbound Testing,” “Mix Probiotics, Supplements, and Veggies,” and “Outbound Testing.” Your food safety plan identified the following preventive controls for the hazard of pathogens: “Supply Chain: Approved Supplier,” “Probiotics,” and “Outbound Micro Testing.” During the inspection, your firm provided finished product microbial test results for cat and dog food manufactured between August 2021- August 2022 showing 49 products tested positive for \u003Cem>Listeria monocytogenes\u003C\u002Fem> or \u003Cem>Salmonella\u003C\u002Fem> spp. These positive results demonstrate the controls you have identified are not effectively and significantly minimizing or preventing the hazard of pathogens. An indication the controls you implemented are not adequate is that FDA laboratory analysis detected \u003Cem>Listeria monocytogenes\u003C\u002Fem> in an FDA surveillance sample (number 1146079) of your pet food, “Raw Frozen Primal Patties for Dogs Beef Formula,” collected from retail on May 24, 2022, resulting in the July 6, 2022, Class I recall described above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Evaluation of your response:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your response stated your firm will no longer utilize supplier approval or outbound microbiological testing as preventive controls for pathogens. You identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the preventive control for frozen products and probiotic inclusion as the preventive control for freeze dried products. Your supplier approval has been reclassified as a supporting prerequisite program and finished product microbiological testing has been changed to a verification activity. Additionally, you added a sanitation preventive control, and you state training will be provided on the new procedures. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide adequate supporting documentation to demonstrate these corrections have been completed and consistently implemented.\u003C\u002Fp>\n\n\u003Cp>2. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your reliance on your testing prerequisite program failed to reduce the probability that a nutrient deficiency or toxicity will occur in your pet food in the absence of a preventive control. In your Hazard Analysis at the “Mix Supplements and Veggies” step, you identified and evaluated the potential chemical hazard of the addition of Vitamin D and Thiamin as a significant hazard and determined it did not require a preventive control due to your testing prerequisite program. However, your prerequisite program was either insufficient or you failed to implement it adequately to manage the hazard. Specifically,\u003C\u002Fp>\n\n\u003Cp>a)&nbsp; The lab report numbered 21-124-9881 with a sample received date of April 23, 2021, for the product Canine Turkey &amp; Sardine Formula Freeze Dried (lot W10031394) reported Vitamin D3 levels, based on dry weight, as 3,410 IU\u002Fkg. Your firm’s Standard Operating Procedure (SOP), SOP-722, “Sampling Protocol for Thiamine and Vitamin D,” identifies a maximum vitamin D3 level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> IU\u002Fkg based on dry weight. Your corrective actions inSOP-722 state, “If the levels of vitamin D exceed the requirements the product will be destroyed.” However, your firm distributed the Canine Turkey &amp; Sardine Formula Freeze Dried (lot W10031394) on April 22, 2021. Additionally, you distributed this food before the lab had even received the samples, making it impossible for you to have destroyed the food in accordance with SOP-722. Finally, your firm was not consistently testing the finished products for total Vitamin D (D2 and D3) levels, despite the fact that some of your ingredients contain Vitamin D2, which could contribute to elevated levels of Vitamin D in your dog food.\u003C\u002Fp>\n\n\u003Cp>b)&nbsp; Although you told the Investigator that you utilize the AAFCO Food Nutrient Profiles, the table on page 2 of your SOP-722 identified a minimum thiamine level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fkg based on a dry weight in feline diets. The AAFCO Food Nutrient Profiles for thiamine in feline diets identifies a minimum level of 5.6 mg\u002Fkg. As a result, your prerequisite program is insufficient to manage a thiamine deficiency hazard. For example, the lab report numbered 21-029-9570 with a sample received date of January 14, 2021, for the product Feline Chicken &amp; Salmon Formula Freeze Dried (lot W10022504), reported thiamine levels based on dry weight as 3.96 mg\u002Fkg. Your firm distributed the Feline Chicken &amp; Salmon Formula Freeze Dried (lot W10022504) with a low thiamine level on January 11, 2021.Additionally, you distributed this food before the lab had even received the samples, making it impossible for you to have reworked the food in accordance with SOP-722, even if you had been aware of a low level of thiamine.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Evaluation of your response:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your response stated you identified a new third party lab for all chemical testing and your testing method for vitamin D will include both vitamin D2 and D3; SOP-722 will be retired and product sampling, inspection and analysis SOP &amp; guidelines will be updated; the addition of ingredients containing vitamin D and thiamine will be verified by review and sign-off; job cards for all products will be updated with current batch recipe amounts; training will be provided on the new supplement addition process; and your food safety plan and hazard analysis are being reviewed and updated with the assistance of a new food safety consultation company. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide supporting documentation to demonstrate these corrections have been completed and are being consistently implemented.\u003C\u002Fp>\n\n\u003Cp>3. You did not validate that the process preventive control you identified and implemented in accordance with 21 CFR 507.34 is adequate to control the hazard as appropriate to the nature of the preventive control and its role in your facility’s food safety system, as required by 21CFR 507.47(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm adds \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preventive control for pathogens for your freeze-dried products. The FDA reviewed your validation study for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preventive control for \u003Cem>Salmonella\u003C\u002Fem> in your freeze-dried beef products and we determined your validation study did not support your claim that the probiotic is an effective preventive control for \u003Cem>Salmonella\u003C\u002Fem>. The validation study did not report whether \u003Cem>Salmonella\u003C\u002Fem> was detected below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fg. FDA considers even very small amounts of \u003Cem>Salmonella\u003C\u002Fem> in a pet food distributed to consumers to adulterate the food and preventive controls must ensure that animal food will not be adulterated. [See 21 CFR 507.34(a)(1)]. Also, your validation study does not address the other pathogens you have determined to be hazards requiring a preventive control, such as E. coli O157:H7 and \u003Cem>Listeria monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Evaluation of your response:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your response included a revised report of the validation study conducted by \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the inhibition of \u003Cem>Salmonella\u003C\u002Fem> using \u003Cstrong>(b)(4)\u003C\u002Fstrong> with updated graphs and language. After a review of your revised validation study report, FDA still concludes your study does not support your claim that the probiotic is an effective preventive control for Salmonella in freeze dried, raw beef; therefore, your response is inadequate. Your revised study indicates \u003Cstrong>(b)(4)\u003C\u002Fstrong> detection was performed using the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for \u003Cem>Salmonella\u003C\u002Fem>, following \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodology. However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not an applicable method for your process. Probiotics present in treated freeze-dried raw beef samples contain high levels of background flora which can suppress the growth of \u003Cem>Salmonella\u003C\u002Fem> and decrease the sensitivity of detecting \u003Cem>Salmonella\u003C\u002Fem>. Additionally, although the revised study report references “Selective Enrichment,” you used non-selective \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a non-selective \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Selective enrichment broths for samples with high levels of probiotics help facilitate the growth of \u003Cem>Salmonella\u003C\u002Fem> while also suppressing the growth of the background flora without decreasing the sensitivity of detecting \u003Cem>Salmonella\u003C\u002Fem>. Furthermore, your study report also indicated you performed an enumeration of \u003Cem>Salmonella\u003C\u002Fem> by following FDA’s Bacteriological Analytical Manual (BAM); however, FDA BAM does not have a method for \u003Cem>Salmonella\u003C\u002Fem> enumeration and the method used in the study is not able to detect ˂10 CFU\u002Fg of \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Your response also provided a protocol for a validation study to be conducted by \u003Cstrong>(b)(4)\u003C\u002Fstrong> for using \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preventive control for \u003Cem>Listeria monocytogenes\u003C\u002Fem> in freeze-dried products. You indicated the initial report from \u003Cstrong>(b)(4)\u003C\u002Fstrong> would be available in December 2022. We are unable to further evaluate this corrective action until we can review the final study report.\u003C\u002Fp>\n\n\u003Cp>4. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as provided in 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan, as required by 507.42(b)(2).\u003C\u002Fp>\n\n\u003Cp>Specifically, on July 6, 2022, your firm recalled Raw Frozen Primal Patties for Dogs Beef Formula, lot W10068709, with a production date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, after an FDA surveillance sample of the lot revealed the presence of \u003Cem>Listeria monocytogenes\u003C\u002Fem>. Your preventive controls for the hazard of pathogens were found to be ineffective; therefore, you are required to take corrective action to identify and correct the problem, reduce the likelihood the problem will recur, and evaluate all affected animal food for safety. During FDA’s inspection, our review of your “Grind Line Temperature Inspection” form for \u003Cstrong>(b)(4)\u003C\u002Fstrong> line \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicated your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> products before and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products after the recalled lot. Your firm does not perform cleaning between batches of the same recipe and only performs a \u003Cstrong>(b)(4)\u003C\u002Fstrong> when transitioning between different recipes. Your firm failed to evaluate the safety of the products manufactured on the same date and line as the recalled lot. In addition, your firm failed to reduce the likelihood the problem will recur as evidenced by your testing showing four lots of finished product found positive for pathogens after implementation of your corrective actions in response to the recall.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Evaluation of your response:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your response stated you are updating your food safety plan to add a sanitation preventive control and will review and update all associated procedures, checklists, and pre-operational instructions. In addition, you are updating your good manufacturing practices and will provide training on your new procedures, increase your environmental monitoring swab sites, and will provide training on your CAPA procedures. You also stated that if any product tests positive on a particular shift, all product manufactured on that shift will be sent for rework. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide adequate supporting documentation to demonstrate the promised corrections have been completed and consistently implemented.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\n\n\u003Cp>• Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fa>\u003Cbr>\n• Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fa>\u003Cbr>\n• Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez\u003Cbr>\nDirector Compliance Branch\u003Cbr>\nFood &amp; Drug Administration\u003Cbr>\nHAF Division West 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Or emailed to: orahafwest5firmresponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to the Unique Identification Number (CMS 645467) when replying.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@fda.hhs.gov , or (949) 608-4496.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations- West Division 5\u003C\u002Fp>\n\n\u003Cp>CC: Matthew Koss, Founder\u002FChief Product Officer via email @ Matt@primalpetgroup.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTimothy Simonds\n\nRecipient Title\n\nCEO\n\nPrimal Pet Foods, Inc.\n\n535 Watt Drive, Suite B\n\nFairfield, CA 94534-1790\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nFebruary 21, 2023\n\nWL 645467\n\nDear Mr. Simonds:\n\nThe United States Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 535 Watt Drive, Suite B, Fairfield, CA 94534-1790 from July 14 through October 11, 2022. This inspection was conducted in response to a Class 1 recall initiated on July 6, 2022, of Raw Frozen Primal Patties for Dogs Beef Formula, lot number W10068709, due to the presence of Listeria monocytogenes detected in an FDA surveillance sample.\n\nOur inspection revealed evidence of significant violations of FDA’s Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals regulation, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated.1 The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.2 Also, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.3\n\nYou may find the FD&C Act and FDA’s regulations through links in FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, you were issued a Form FDA-483, Inspectional Observations. We received your written response dated November 1, 2022. We have reviewed your response and we discuss your corrective actions below, in relation to each of the noted violations.\n\nHazard Analysis and Risk-Based Preventive Controls Requirements\n\nYour animal food facility is subject to the Hazard Analysis and Risk-Based Preventive Controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During our inspection of your facility, the FDA Investigator observed evidence of significant violations of these requirements including, but not limited to, the following:\n\n1. You did not identify and implement preventive controls to provide assurances that anyhazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\n\nSpecifically, your firm manufactures raw frozen and raw freeze-dried pet food and treats for dogs and cats. Your hazard analysis determined pathogens (Salmonella spp., Listeria monocytogenes, and E. coli O157:H7) are a hazard requiring a preventive control at the following steps: “Inbound Testing,” “Mix Probiotics, Supplements, and Veggies,” and “Outbound Testing.” Your food safety plan identified the following preventive controls for the hazard of pathogens: “Supply Chain: Approved Supplier,” “Probiotics,” and “Outbound Micro Testing.” During the inspection, your firm provided finished product microbial test results for cat and dog food manufactured between August 2021- August 2022 showing 49 products tested positive for Listeria monocytogenes or Salmonella spp. These positive results demonstrate the controls you have identified are not effectively and significantly minimizing or preventing the hazard of pathogens. An indication the controls you implemented are not adequate is that FDA laboratory analysis detected Listeria monocytogenes in an FDA surveillance sample (number 1146079) of your pet food, “Raw Frozen Primal Patties for Dogs Beef Formula,” collected from retail on May 24, 2022, resulting in the July 6, 2022, Class I recall described above.\n\nEvaluation of your response:\n\nYour response stated your firm will no longer utilize supplier approval or outbound microbiological testing as preventive controls for pathogens. You identified (b)(4) as the preventive control for frozen products and probiotic inclusion as the preventive control for freeze dried products. Your supplier approval has been reclassified as a supporting prerequisite program and finished product microbiological testing has been changed to a verification activity. Additionally, you added a sanitation preventive control, and you state training will be provided on the new procedures. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide adequate supporting documentation to demonstrate these corrections have been completed and consistently implemented.\n\n2. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\n\nSpecifically, your reliance on your testing prerequisite program failed to reduce the probability that a nutrient deficiency or toxicity will occur in your pet food in the absence of a preventive control. In your Hazard Analysis at the “Mix Supplements and Veggies” step, you identified and evaluated the potential chemical hazard of the addition of Vitamin D and Thiamin as a significant hazard and determined it did not require a preventive control due to your testing prerequisite program. However, your prerequisite program was either insufficient or you failed to implement it adequately to manage the hazard. Specifically,\n\na) The lab report numbered 21-124-9881 with a sample received date of April 23, 2021, for the product Canine Turkey & Sardine Formula Freeze Dried (lot W10031394) reported Vitamin D3 levels, based on dry weight, as 3,410 IU\u002Fkg. Your firm’s Standard Operating Procedure (SOP), SOP-722, “Sampling Protocol for Thiamine and Vitamin D,” identifies a maximum vitamin D3 level of (b)(4) IU\u002Fkg based on dry weight. Your corrective actions inSOP-722 state, “If the levels of vitamin D exceed the requirements the product will be destroyed.” However, your firm distributed the Canine Turkey & Sardine Formula Freeze Dried (lot W10031394) on April 22, 2021. Additionally, you distributed this food before the lab had even received the samples, making it impossible for you to have destroyed the food in accordance with SOP-722. Finally, your firm was not consistently testing the finished products for total Vitamin D (D2 and D3) levels, despite the fact that some of your ingredients contain Vitamin D2, which could contribute to elevated levels of Vitamin D in your dog food.\n\nb) Although you told the Investigator that you utilize the AAFCO Food Nutrient Profiles, the table on page 2 of your SOP-722 identified a minimum thiamine level of (b)(4) mg\u002Fkg based on a dry weight in feline diets. The AAFCO Food Nutrient Profiles for thiamine in feline diets identifies a minimum level of 5.6 mg\u002Fkg. As a result, your prerequisite program is insufficient to manage a thiamine deficiency hazard. For example, the lab report numbered 21-029-9570 with a sample received date of January 14, 2021, for the product Feline Chicken & Salmon Formula Freeze Dried (lot W10022504), reported thiamine levels based on dry weight as 3.96 mg\u002Fkg. Your firm distributed the Feline Chicken & Salmon Formula Freeze Dried (lot W10022504) with a low thiamine level on January 11, 2021.Additionally, you distributed this food before the lab had even received the samples, making it impossible for you to have reworked the food in accordance with SOP-722, even if you had been aware of a low level of thiamine.\n\nEvaluation of your response:\n\nYour response stated you identified a new third party lab for all chemical testing and your testing method for vitamin D will include both vitamin D2 and D3; SOP-722 will be retired and product sampling, inspection and analysis SOP & guidelines will be updated; the addition of ingredients containing vitamin D and thiamine will be verified by review and sign-off; job cards for all products will be updated with current batch recipe amounts; training will be provided on the new supplement addition process; and your food safety plan and hazard analysis are being reviewed and updated with the assistance of a new food safety consultation company. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide supporting documentation to demonstrate these corrections have been completed and are being consistently implemented.\n\n3. You did not validate that the process preventive control you identified and implemented in accordance with 21 CFR 507.34 is adequate to control the hazard as appropriate to the nature of the preventive control and its role in your facility’s food safety system, as required by 21CFR 507.47(a).\n\nSpecifically, your firm adds (b)(4) as a preventive control for pathogens for your freeze-dried products. The FDA reviewed your validation study for the use of (b)(4) as a preventive control for Salmonella in your freeze-dried beef products and we determined your validation study did not support your claim that the probiotic is an effective preventive control for Salmonella. The validation study did not report whether Salmonella was detected below (b)(4) CFU\u002Fg. FDA considers even very small amounts of Salmonella in a pet food distributed to consumers to adulterate the food and preventive controls must ensure that animal food will not be adulterated. [See 21 CFR 507.34(a)(1)]. Also, your validation study does not address the other pathogens you have determined to be hazards requiring a preventive control, such as E. coli O157:H7 and Listeria monocytogenes.\n\nEvaluation of your response:\n\nYour response included a revised report of the validation study conducted by (b)(4) for the inhibition of Salmonella using (b)(4) with updated graphs and language. After a review of your revised validation study report, FDA still concludes your study does not support your claim that the probiotic is an effective preventive control for Salmonella in freeze dried, raw beef; therefore, your response is inadequate. Your revised study indicates (b)(4) detection was performed using the “(b)(4)” for Salmonella, following (b)(4) methodology. However, (b)(4) is not an applicable method for your process. Probiotics present in treated freeze-dried raw beef samples contain high levels of background flora which can suppress the growth of Salmonella and decrease the sensitivity of detecting Salmonella. Additionally, although the revised study report references “Selective Enrichment,” you used non-selective (b)(4) and a non-selective (b)(4). Selective enrichment broths for samples with high levels of probiotics help facilitate the growth of Salmonella while also suppressing the growth of the background flora without decreasing the sensitivity of detecting Salmonella. Furthermore, your study report also indicated you performed an enumeration of Salmonella by following FDA’s Bacteriological Analytical Manual (BAM); however, FDA BAM does not have a method for Salmonella enumeration and the method used in the study is not able to detect ˂10 CFU\u002Fg of Salmonella.\n\nYour response also provided a protocol for a validation study to be conducted by (b)(4) for using (b)(4) as a preventive control for Listeria monocytogenes in freeze-dried products. You indicated the initial report from (b)(4) would be available in December 2022. We are unable to further evaluate this corrective action until we can review the final study report.\n\n4. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as provided in 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan, as required by 507.42(b)(2).\n\nSpecifically, on July 6, 2022, your firm recalled Raw Frozen Primal Patties for Dogs Beef Formula, lot W10068709, with a production date of (b)(4), after an FDA surveillance sample of the lot revealed the presence of Listeria monocytogenes. Your preventive controls for the hazard of pathogens were found to be ineffective; therefore, you are required to take corrective action to identify and correct the problem, reduce the likelihood the problem will recur, and evaluate all affected animal food for safety. During FDA’s inspection, our review of your “Grind Line Temperature Inspection” form for (b)(4) line (b)(4) indicated your firm manufactured (b)(4) products before and (b)(4) products after the recalled lot. Your firm does not perform cleaning between batches of the same recipe and only performs a (b)(4) when transitioning between different recipes. Your firm failed to evaluate the safety of the products manufactured on the same date and line as the recalled lot. In addition, your firm failed to reduce the likelihood the problem will recur as evidenced by your testing showing four lots of finished product found positive for pathogens after implementation of your corrective actions in response to the recall.\n\nEvaluation of your response:\n\nYour response stated you are updating your food safety plan to add a sanitation preventive control and will review and update all associated procedures, checklists, and pre-operational instructions. In addition, you are updating your good manufacturing practices and will provide training on your new procedures, increase your environmental monitoring swab sites, and will provide training on your CAPA procedures. You also stated that if any product tests positive on a particular shift, all product manufactured on that shift will be sent for rework. We are unable to fully evaluate the adequacy of your corrective actions since you did not provide adequate supporting documentation to demonstrate the promised corrections have been completed and consistently implemented.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal action, including without limitation, seizure and injunction.\n\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\n\n• Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\n\n• Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\n\n• Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to:\n\nSergio Chavez\n\nDirector Compliance Branch\n\nFood & Drug Administration\n\nHAF Division West 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nOr emailed to: orahafwest5firmresponses@fda.hhs.gov.\n\nRefer to the Unique Identification Number (CMS 645467) when replying.\n\nIf you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@fda.hhs.gov , or (949) 608-4496.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations- West Division 5\n\nCC: Matthew Koss, Founder\u002FChief Product Officer via email @ Matt@primalpetgroup.com\n\n_____________________\n\n1 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n\n2 See Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\n3 See Section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].","Primal Pet Foods, Inc.","primal-pet-foods-inc-645467-02212023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprimal-pet-foods-inc-645467-02212023","2026-10-26T08:09:44.002539+00:00","2023-03-14","645467","Animal & VeterinaryFood & Beverages","Division of Human and Animal Food Operations West V","Timothy Simonds","2026-08-20T01:12:33.857+00:00","United Parcel Service","2023-02-21",{"id":74,"raw":75,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":43,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":88,"body_fetched_at":89,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},388,[76,77,78,37,79,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sports-nutrition-719433-12122025\">Prime Sports Nutrition\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Fernando Arias\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Prime Sports Nutrition\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4800 White Ln., Suite G\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bakersfield\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93309\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@shopteamprime.com\"> info@shopteamprime.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@primesportsnutrition.com\"> info@primesportsnutrition.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 719433\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Fernando Arias:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprimesportsnutrition.com\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “LGD-4033” (also referred to on your website as “Ligandrol”), “RAD-140” (also referred to on your website as “Testolone”), “MK-677” (also referred to on your website as “Ibutamoren”), and “S-23” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>FDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing some of your products as a “RESEARCH COMPOUND” and “NOT FOR HUMAN CONSUMPTION,” evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>LGD-4033 Ligandrol\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Flgd-4033-galactic-plus:\u003C\u002Fp>\u003Cul>\u003Cli>“Looking To Build Lean Mass And Improving Strength While Maximizing Your Fat Loss Potential. LGD-4033 Has You Covered. LGD Is A Selective Androgen Receptor Modulator (SARM) That Usually Goes By The Name Ligandrol. It’s Known For Its Muscle Mass And Strength Increasing Properties That Actually Don’t Come With The Anabolic Side Effects. This Is What Makes It So Popular With Bodybuilders And Athletes. Ligandrol Acts Similar To An Anabolic Based Substance. It Has The Ability To Rapidly Increase Muscle Mass While Reducing Overall Body Fat. Increased Muscle Mass And An Increase In Strength Are Both Results Of The Selective Activation Of Androgen Receptors In The Muscles.”\u003C\u002Fli>\u003Cli>“KEY BENEFITS\u003Cbr>o Improves Muscle Mass\u003Cbr>o Improve Stamina\u003Cbr>o Burns Body Fat\u003Cbr>o Boosts Testosterone”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>RAD-140 Testolone\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fgalactic-plus-duo-mk677-rad140-1?_pos=4&amp;_sid=9711d0e06&amp;_ss=r:\u003C\u002Fp>\u003Cul>\u003Cli>“RAD140 + MK677 is A Very Popular Pairing.”\u003C\u002Fli>\u003Cli>“Many Across The World Are Admiring RAD-140 For Countless Reasons. Testolone RAD140 Was Designed As A Safer Alternative To Anabolics. This Highly Anabolic Compound Promotes Increases In Muscle Mass And Is Second To None For Mimicking The Effects Of Natural Testosterone.”\u003C\u002Fli>\u003Cli>“Benefits Of Testolone (RAD140)\u003Cbr>o Anabolic To Androgenic Ratio of 90:1\u003Cbr>o Improves Libido And Sexual Performance\u003Cbr>o Best SARM For Muscle Growth And Size.\u003Cbr>o Reduces Fat And Increases Muscle Mass.\u003Cbr>o Ideal To Enhance Body Composition.\u003Cbr>o Rapid Muscle Recovery”\u003C\u002Fli>\u003Cli>“Medical Studies Have Demonstrated (And As Confirmed By Online Reviews About Testolone) That RAD-140 Is Highly Effective To Treat Degenerative Conditions Like Alzheimer's Disease. It Is Equally Effective To Provide Relief To Subjects With Androgenic Deficiencies.”\u003C\u002Fli>\u003Cli>“Individuals Treated With Testolone Have Reported Improvements In The Levels Of Sexual Development And Function.”\u003C\u002Fli>\u003Cli>“The Use Of Testolone Is Associated By RAD-140 Users With Dramatic Relief From Muscle Wasting Or Loss Or Muscle Tissue, Weakness, And Fatigue That Makes The Entire Otherwise-Complicated Processes Of Healing And Recovery Easy And Quick.”\u003C\u002Fli>\u003Cli>“RAD-140 Users Can Expect Dramatic Fat Loss And Gain 5-15 Lbs Lean Muscle Mass Gains In As Short As Four To Six Weeks.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MK-677 Ibutamoren\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fgalactic-plus-duo-mk677-rad140-1?_pos=4&amp;_sid=9711d0e06&amp;_ss=r:\u003C\u002Fp>\u003Cul>\u003Cli>“Benefits Of Ibutamoren (MK-677)\u003Cbr>o Increases Muscle Mass and Strength\u003Cbr>o Improves Tissue Regeneration\u003Cbr>o Increases Growth Hormone Levels\u003Cbr>o Clinically Proven GH Elevator\u003Cbr>o Enhanced Vitality And Faster Recovery\u003Cbr>o Reduces Body Fat\u003Cbr>o Increases Sleep Quality And Rapid Eye Movement (REM) Sleep\u003Cbr>o Increases Insulin-Like Growth Factor 1 (IGF-1)\u003Cbr>o Improves Basal Metabolic Rate”\u003C\u002Fli>\u003Cli>“MK-677 + RAD 140 is Normally Used 12 Weeks”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>S-23\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fs23-galactic-plus-1:\u003C\u002Fp>\u003Cul>\u003Cli>“Looking To Boost Strength While Obliterating Fat? Let Us Introduce You To S23! One Of The Most Potent SARMs On The Market, Some Say That S-23 Is The Closest Thing To Conventional Steroids That You Can Get. An Excellent Cutting Compound, It Boosts Fat Loss Whilst Offering Impressive Lean, Dry Gains. This Compound Is Renowned For Developing A Dense, Hard Aesthetic With No Water Retention. If You’re Looking For Grainy-Looking Muscles, Then You Should Definitely Consider S-23.”\u003C\u002Fli>\u003Cli>“KEY BENEFITS\u003Cbr>o Muscle Mass Increase\u003Cbr>o Fat Loss\u003Cbr>o Increased Endurance\u003Cbr>o Recover Times Are Shorter.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products marketed as SARMs are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719433” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nFernando Arias\n\nRecipient Title\n\nOwner\n\nPrime Sports Nutrition\n\n4800 White Ln., Suite G\n\nBakersfield, CA 93309\n\nUnited States\n\ninfo@shopteamprime.com\n\ninfo@primesportsnutrition.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 12, 2025\nRE: 719433\nFernando Arias:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprimesportsnutrition.com\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “LGD-4033” (also referred to on your website as “Ligandrol”), “RAD-140” (also referred to on your website as “Testolone”), “MK-677” (also referred to on your website as “Ibutamoren”), and “S-23” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nFDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.1\nDespite statements on your product labeling marketing some of your products as a “RESEARCH COMPOUND” and “NOT FOR HUMAN CONSUMPTION,” evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nLGD-4033 Ligandrol\nOn the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Flgd-4033-galactic-plus:\n“Looking To Build Lean Mass And Improving Strength While Maximizing Your Fat Loss Potential. LGD-4033 Has You Covered. LGD Is A Selective Androgen Receptor Modulator (SARM) That Usually Goes By The Name Ligandrol. It’s Known For Its Muscle Mass And Strength Increasing Properties That Actually Don’t Come With The Anabolic Side Effects. This Is What Makes It So Popular With Bodybuilders And Athletes. Ligandrol Acts Similar To An Anabolic Based Substance. It Has The Ability To Rapidly Increase Muscle Mass While Reducing Overall Body Fat. Increased Muscle Mass And An Increase In Strength Are Both Results Of The Selective Activation Of Androgen Receptors In The Muscles.”\n“KEY BENEFITS\no Improves Muscle Mass\no Improve Stamina\no Burns Body Fat\no Boosts Testosterone”\nRAD-140 Testolone\nOn the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fgalactic-plus-duo-mk677-rad140-1?_pos=4&_sid=9711d0e06&_ss=r:\n“RAD140 + MK677 is A Very Popular Pairing.”\n“Many Across The World Are Admiring RAD-140 For Countless Reasons. Testolone RAD140 Was Designed As A Safer Alternative To Anabolics. This Highly Anabolic Compound Promotes Increases In Muscle Mass And Is Second To None For Mimicking The Effects Of Natural Testosterone.”\n“Benefits Of Testolone (RAD140)\no Anabolic To Androgenic Ratio of 90:1\no Improves Libido And Sexual Performance\no Best SARM For Muscle Growth And Size.\no Reduces Fat And Increases Muscle Mass.\no Ideal To Enhance Body Composition.\no Rapid Muscle Recovery”\n“Medical Studies Have Demonstrated (And As Confirmed By Online Reviews About Testolone) That RAD-140 Is Highly Effective To Treat Degenerative Conditions Like Alzheimer's Disease. It Is Equally Effective To Provide Relief To Subjects With Androgenic Deficiencies.”\n“Individuals Treated With Testolone Have Reported Improvements In The Levels Of Sexual Development And Function.”\n“The Use Of Testolone Is Associated By RAD-140 Users With Dramatic Relief From Muscle Wasting Or Loss Or Muscle Tissue, Weakness, And Fatigue That Makes The Entire Otherwise-Complicated Processes Of Healing And Recovery Easy And Quick.”\n“RAD-140 Users Can Expect Dramatic Fat Loss And Gain 5-15 Lbs Lean Muscle Mass Gains In As Short As Four To Six Weeks.”\nMK-677 Ibutamoren\nOn the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fgalactic-plus-duo-mk677-rad140-1?_pos=4&_sid=9711d0e06&_ss=r:\n“Benefits Of Ibutamoren (MK-677)\no Increases Muscle Mass and Strength\no Improves Tissue Regeneration\no Increases Growth Hormone Levels\no Clinically Proven GH Elevator\no Enhanced Vitality And Faster Recovery\no Reduces Body Fat\no Increases Sleep Quality And Rapid Eye Movement (REM) Sleep\no Increases Insulin-Like Growth Factor 1 (IGF-1)\no Improves Basal Metabolic Rate”\n“MK-677 + RAD 140 is Normally Used 12 Weeks”\nS-23\nOn the webpage https:\u002F\u002Fprimesportsnutrition.com\u002Fproducts\u002Fs23-galactic-plus-1:\n“Looking To Boost Strength While Obliterating Fat? Let Us Introduce You To S23! One Of The Most Potent SARMs On The Market, Some Say That S-23 Is The Closest Thing To Conventional Steroids That You Can Get. An Excellent Cutting Compound, It Boosts Fat Loss Whilst Offering Impressive Lean, Dry Gains. This Compound Is Renowned For Developing A Dense, Hard Aesthetic With No Water Retention. If You’re Looking For Grainy-Looking Muscles, Then You Should Definitely Consider S-23.”\n“KEY BENEFITS\no Muscle Mass Increase\no Fat Loss\no Increased Endurance\no Recover Times Are Shorter.”\nYour products marketed as SARMs are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719433” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n______________________________\n1 See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.","Prime Sports Nutrition","prime-sports-nutrition-719433-12122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sports-nutrition-719433-12122025","2026-10-26T08:09:44.12626+00:00","2025-12-23","719433","Fernando Arias","2026-08-19T07:20:18.015+00:00","2025-12-12",{"id":92,"raw":93,"subject":98,"body_html":99,"body_text":100,"firm_name":101,"letter_id":102,"created_at":18,"fei_number":19,"letter_url":103,"updated_at":104,"action_type":22,"case_status":23,"posted_date":105,"marcs_cms_no":106,"product_type":107,"closeout_date":19,"issuing_office":97,"recipient_name":108,"body_fetched_at":109,"delivery_method":110,"recipient_title":19,"reference_number":106,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},1830,[94,95,96,97,98,13,13,13],"\u003Ctime datetime=\"2023-09-26T13:20:00Z\">09\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-winson-prima-sejahtera-660935-09052023\">PT. Winson Prima Sejahtera\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>660935\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Albert Winson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>PT. Winson Prima Sejahtera\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Jl. Pulau Solor No. 11 KIM-11\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saentis, Percut Sei Tuan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sumatera Utara\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Sumatra\u003C\u002Fspan> \u003Cspan>20371\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indonesia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Albert.winson@gmail.com\"> Albert.winson@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 660935\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Albert Winson:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, located at Jl. Pulau Solor No. 11 KIM-11 Saentis, Percut Sei Tuan, North Sumatra, Sumatera Utara, Indonesia 20371, on April 02 - 09, 2023. During the remote assessment, we found that you had serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. To date, your firm has not responded to the discussion items identified during the FFRA.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), [21 U.S.C. § 342(a)(4)]. Accordingly, your wild, frozen, vacuum packaged, ready-to-eat yellowfin tuna is adulterated, in that it has been prepared, packed, or held under conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the \u003Cem>Fish and Fisheries Products Hazards and Controls Guidance\u003C\u002Fem> (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must conduct or have conducted a hazard analysis for your wild, frozen, vacuum packaged, ready-to-eat yellowfin tuna that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s HACCP plan does not list the food safety hazard of pathogen growth, including \u003Cem>Salmonella\u003C\u002Fem>, which can be introduced during \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing steps for your ready-to-eat raw tuna products (e.g., ground tuna, saku, tuna chunks). Cumulative time exposures should be limited to 2 hours when ambient temperatures (e.g., water, air) are not controlled and\u002For exceed 21.1°C (70°F) to prevent pathogen growth.\u003C\u002Fp>\n\n\u003Cp>2. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP plan lists a critical limit “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical control point that does not provide the necessary safety assurance needed to prevent histamine formation as required by 21 CFR 123.6(c)(3). FDA recommends listing critical limits that address the ambient temperature (e.g. air, water) in the storage area to assure the safety of all fish units.\u003C\u002Fp>\n\n\u003Cp>3. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). Your firm’s HACCP plan lists a monitoring procedure “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the receiving critical control point (CCP) to control scombrotoxin (histamine) formation. However, you are not implementing the recordkeeping system, monitoring procedures, or maintaining the necessary monitoring records as required by 21 CFR 123.6(b). Specifically,\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. Your records show that internal temperatures were not consistently monitored at receiving CCP. For example, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from Supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> showed the internal temperatures were missing for No. 4, 5, 6 and for supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> No. 3. Also, the Receiving Raw Material record dated 31\u002F7\u002F22 No. 74 – 108 was missing internal temperatures.\u003C\u002Fp>\n\n\u003Cp>4. Since you chose to include corrective actions in your HACCP plan, your corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective actions at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical control point for histamine testing, decomposition, and internal temperatures, are not adequate to ensure that affected product is not entered into commerce and that the cause of the deviation was corrected as required by 21 CFR 123.7(b). Specifically,\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. Your corrective action listed “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, does not list controls that address correcting the cause of the critical limit deviations.\u003Cbr>\n&nbsp; &nbsp; b. Your corrective action lists “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for \u003Cstrong>(b)(4)\u003C\u002Fstrong> fish that will be tested for histamine does not include a statement that none of the fish tested should have histamine levels at or above \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm.\u003Cbr>\n&nbsp; &nbsp; c. Your monitoring records dated from August 01 – 20, 2022 corresponding to your corrective action “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” do not show when you implemented the corrective action, in response to your critical limits of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” being exceeded. For example, the Histamine Test Result records showed your critical limits were exceeded, specifically:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;i. August 06, 2022 for Group \u003Cstrong>(b)(4)\u003C\u002Fstrong> shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm histamine\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;ii. August 04, 2022 for Group \u003Cstrong>(b)(4)\u003C\u002Fstrong> shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm histamine and Group \u003Cstrong>(b)(4)\u003C\u002Fstrong> shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm histamine\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp;iii. August 03, 2022 for Group \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm histamine and Group \u003Cstrong>(b)(4)\u003C\u002Fstrong> shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm histamine. No records were provided to the investigator showing the retest results and whether the affected fish were effectively rejected.\u003C\u002Fp>\n\n\u003Cp>Your firm should consistently follow the monitoring procedures and corrective actions to ensure that the seafood products you prepare, pack or hold do not deviate from the indicated control measures established in your HACCP plan.\u003C\u002Fp>\n\n\u003Cp>For additional guidance you may reference the \u003Cem>Fish and Fishery Products Hazards &amp; Controls Guidance\u003C\u002Fem> - June 2022 Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 12 Pathogenic Bacterial Growth and Toxin Formation (Other Than \u003Cem>Clostridium botulinum\u003C\u002Fem>) as a Result of Time and Temperature Abuse.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to Giselle Jordan, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Giselle Jordan via email at Giselle.jordan@fda.hhs.gov. Pease reference CMS #660935 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nReference #:\n\n660935\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Albert Winson\n\nRecipient Title\n\nDirector\n\nPT. Winson Prima Sejahtera\n\nJl. Pulau Solor No. 11 KIM-11\n\nSaentis, Percut Sei Tuan\n\nSumatera Utara\n\nNorth Sumatra 20371\n\nIndonesia\n\nAlbert.winson@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nReference # 660935\n\nDear Mr. Albert Winson:\n\nThe United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, located at Jl. Pulau Solor No. 11 KIM-11 Saentis, Percut Sei Tuan, North Sumatra, Sumatera Utara, Indonesia 20371, on April 02 - 09, 2023. During the remote assessment, we found that you had serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. To date, your firm has not responded to the discussion items identified during the FFRA.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), [21 U.S.C. § 342(a)(4)]. Accordingly, your wild, frozen, vacuum packaged, ready-to-eat yellowfin tuna is adulterated, in that it has been prepared, packed, or held under conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\n\nYour significant deviations are as follows:\n\n1. You must conduct or have conducted a hazard analysis for your wild, frozen, vacuum packaged, ready-to-eat yellowfin tuna that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s HACCP plan does not list the food safety hazard of pathogen growth, including Salmonella, which can be introduced during (b)(4) processing steps for your ready-to-eat raw tuna products (e.g., ground tuna, saku, tuna chunks). Cumulative time exposures should be limited to 2 hours when ambient temperatures (e.g., water, air) are not controlled and\u002For exceed 21.1°C (70°F) to prevent pathogen growth.\n\n2. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP plan lists a critical limit “(b)(4)” at the (b)(4) critical control point that does not provide the necessary safety assurance needed to prevent histamine formation as required by 21 CFR 123.6(c)(3). FDA recommends listing critical limits that address the ambient temperature (e.g. air, water) in the storage area to assure the safety of all fish units.\n\n3. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). Your firm’s HACCP plan lists a monitoring procedure “(b)(4)” at the receiving critical control point (CCP) to control scombrotoxin (histamine) formation. However, you are not implementing the recordkeeping system, monitoring procedures, or maintaining the necessary monitoring records as required by 21 CFR 123.6(b). Specifically,\n\na. Your records show that internal temperatures were not consistently monitored at receiving CCP. For example, your “(b)(4)” from Supplier (b)(4) showed the internal temperatures were missing for No. 4, 5, 6 and for supplier (b)(4) No. 3. Also, the Receiving Raw Material record dated 31\u002F7\u002F22 No. 74 – 108 was missing internal temperatures.\n\n4. Since you chose to include corrective actions in your HACCP plan, your corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective actions at the (b)(4) critical control point for histamine testing, decomposition, and internal temperatures, are not adequate to ensure that affected product is not entered into commerce and that the cause of the deviation was corrected as required by 21 CFR 123.7(b). Specifically,\n\na. Your corrective action listed “(b)(4)”, does not list controls that address correcting the cause of the critical limit deviations.\n\nb. Your corrective action lists “(b)(4)” for (b)(4) fish that will be tested for histamine does not include a statement that none of the fish tested should have histamine levels at or above (b)(4) ppm.\n\nc. Your monitoring records dated from August 01 – 20, 2022 corresponding to your corrective action “(b)(4)” do not show when you implemented the corrective action, in response to your critical limits of “(b)(4)” being exceeded. For example, the Histamine Test Result records showed your critical limits were exceeded, specifically:\n\ni. August 06, 2022 for Group (b)(4) shows (b)(4) ppm histamine\n\nii. August 04, 2022 for Group (b)(4) shows (b)(4) ppm histamine and Group (b)(4) shows (b)(4) ppm histamine\n\niii. August 03, 2022 for Group (b)(4) shows (b)(4) ppm histamine and Group (b)(4) shows (b)(4) ppm histamine. No records were provided to the investigator showing the retest results and whether the affected fish were effectively rejected.\n\nYour firm should consistently follow the monitoring procedures and corrective actions to ensure that the seafood products you prepare, pack or hold do not deviate from the indicated control measures established in your HACCP plan.\n\nFor additional guidance you may reference the Fish and Fishery Products Hazards & Controls Guidance - June 2022 Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 12 Pathogenic Bacterial Growth and Toxin Formation (Other Than Clostridium botulinum) as a Result of Time and Temperature Abuse.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nYou should direct your written reply to Giselle Jordan, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Giselle Jordan via email at Giselle.jordan@fda.hhs.gov. Pease reference CMS #660935 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","PT. Winson Prima Sejahtera","pt-winson-prima-sejahtera-660935-09052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-winson-prima-sejahtera-660935-09052023","2026-10-26T08:09:45.289186+00:00","2023-09-26","660935","Food & Beverages","Mr. Albert Winson","2026-08-20T00:38:50.295+00:00","Via Express Delivery","2023-09-05",{"id":113,"raw":114,"subject":118,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":123,"fei_number":19,"letter_url":124,"updated_at":125,"action_type":22,"case_status":23,"posted_date":126,"marcs_cms_no":127,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":128,"body_fetched_at":129,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":130,"medical_device_id":19,"response_letter_date":19},1129,[115,116,117,37,118,13,13,13],"\u003Ctime datetime=\"2024-12-17T14:20:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-10T05:00:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-vitality-inc-dba-prime-peptides-695156-12102024\">Prime Vitality, Inc. dba Prime Peptides\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Curtis Miller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Vitality, Inc. dba Prime Peptides\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>735 State St., Ste 422\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Barbara\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@primepeptides.co\"> info@primepeptides.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>695156\u003C\u002Fp>\u003Cp>December 10, 2024\u003C\u002Fp>\u003Cp>Dear Curtis Miller:&nbsp;&nbsp;&nbsp;&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fprimepeptides.co in October 2024 and has observed that your website offers various products as “peptides” including, “Semaglutide” and “Retatrutide.” &nbsp;We have also reviewed your social media websites at www.facebook.com\u002Fprimepeptidesco, www.instagram.com\u002Fprimepeptidesco, and www.youtube.com\u002F@PrimePeptide. &nbsp;Your social media websites direct consumers to your https:\u002F\u002Fprimepeptides.co website to purchase your products. &nbsp;As described below, your “Semaglutide” and “Retatrutide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “research purposes only” and “not for human consumption or clinical use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. &nbsp;Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. &nbsp;Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Fprimepeptides.co\u002Fproducts\u002Fbuy-semaglutide:\u003C\u002Fp>\u003Cp>• “Semaglutide reduces cardiovascular events. The SELECT trial showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with preexisting cardiovascular disease and obesity. This included fewer heart attacks and strokes compared to those on placebo.”\u003C\u002Fp>\u003Cp>• “Semaglutide improves insulin resistance. A study found that semaglutide helped improve insulin sensitivity in participants, which is crucial for managing and preventing type 2 diabetes. This improvement was seen alongside significant weight loss.”\u003C\u002Fp>\u003Cp>• “Mechanism of Action[,] GLP-1 Receptor Activation[,] Appetite Regulation[,] Slowing Gastric Emptying[,] Enhancing Insulin Secretion[,] Reducing Glucagon Production[,] Cardiovascular Benefits[,and] Energy Expenditure and Lipid Metabolism”\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Fprimepeptides.co\u002Fproducts\u002Fbuy-retatrutide:\u003C\u002Fp>\u003Cp>• “Retatrutide improves glycemic control. In a study involving patients with type 2 diabetes, retatrutide reduced HbAlc levels by up to 2.02% at 24 weeks. This indicates better blood sugar control, which is crucial for managing diabetes.”\u003C\u002Fp>\u003Cp>• “Retatrutide enhances cardiometabolic health. Participants in the trial experienced improvements in cardiometabolic measures, including reductions in waist circumference, blood pressure, and lipid levels. For examples, waist circumference decreased by up to 19.6 cm in some participants.”\u003C\u002Fp>\u003Cp>• “Retatrutide reduces liver fat. A 48-week study showed that retatrutide significantly reduced liver fat in obese patients. Those taking 8 mg and 12 mg doses saw liver fat reductions of 23.8% and 25.9% respectively, which is beneficial for liver health.”\u003C\u002Fp>\u003Cp>On your blog post “Top Weight Loss Peptides: Semaglutide, Tirzepatide &amp; More” on your webpage https:\u002F\u002Fprimepeptides.co\u002Fblogs\u002Fpeptides\u002Fweight-loss-peptides:&nbsp;\u003Cbr>• “Top Peptides for Weight Loss: A Quick Guide” with a graphic of a woman with a measuring tape around her waist.\u003C\u002Fp>\u003Cp>o “Semaglutide . . .Pros: Reduces body weight, controls blood sugar levels, FDA-approved for weight management . . . Statistics: Clinical trials show up to 15% body weight loss”\u003C\u002Fp>\u003Cp>o “Retatrutide . . . Pros: Targets 3 pathways, most weight loss, treats fatty live . . . Fun Fact: Known as the ‘triple agonist’ for its multi-pathway approach. Statistics: Early trials indicate up to 25% body weight loss.”\u003C\u002Fp>\u003Cp>• “Semaglutide can help people who are obese or overweight lose a considerable amount of weight and lower their risk of heart disease, diabetes, and cancer when used in combination with diet and exercise.”\u003C\u002Fp>\u003Cp>• “Retatrutide is an emerging peptide developed by Lilly for treating obesity, diabetes, and fatty liver disease. It is common for diabetes medications to be used for weight management, and Retatrutide is a notable example of this trend.”\u003C\u002Fp>\u003Cp>On your social media websites at www.facebook.com\u002Fprimepeptidesco and www.instagram.com\u002Fprimepeptidesco:\u003Cbr>• June 28, 2024 post: “Thanks so much for sharing your experience. We’re so happy to hear you’re loving the benefits! Semaglutide is a GLP-1 receptor agonist known for its significant impact on weight loss, glycemic control, and cardiovascular risk reduction. . . Safe &amp; Effective: Trusted by health professionals worldwide . . . #shareyourexperience #sharingexperience . . . #fitness” with an image of a vial of semaglutide and the text “‘Highly Recommend[,]’ I’ve been using Semaglutide for a few months, and it’s been a game changer. My health and energy levels have improved significantly!”\u003C\u002Fp>\u003Cp>• June 23, 2024 post: “Customer Review Highlight! . . . Hearing about your positive experience means everything to us. So glad you’re loving the benefits! . . . Retatrutide is a new medicine that helps control blood sugar and supports weight loss. . . . Safe &amp; Effective: Trusted by health professionals worldwide . . . #shareyourexperience #sharingexperience . . . #fitness” with an image of a woman in active sportswear, a vial of retatrutide and the text “TESTIMONIALS . . . ‘Impressive Weight Loss[,]’ Retatrutide has been impressive for my weight loss journey. I’ve seen significant results in just a few weeks. Highly recommend!”\u003C\u002Fp>\u003Cp>On your YouTube website at www.youtube.com\u002F@PrimePeptide, August 30, 2024 post “Top 5 Peptides for Weight Loss”:&nbsp;\u003Cbr>• From the text below the video: “Top 5 Peptides for Weight Loss │Effective Fat-Burning Peptides . . . Learn how these peptides work, their potential benefits, and how they can help you achieve your weight loss goals. What You’ll Learn: How Semaglutide and Tirzepatide mimic natural hormones to reduce appetite and promote fat loss. The triple-action approach of Retatrutide for maximum weight reduction.”\u003C\u002Fp>\u003Cp>• From the video: “GLP-1 peptides also improve your overall health by controlling blood sugar and lowering the risk for heart problems, which are often an issue for people who are overweight. Let’s start by talking about the most popular weight loss peptide, semaglutide. Semaglutide is a medication that can help people with weight-related health issues like type 2 diabetes, high cholesterol, and high blood pressure.”\u003C\u002Fp>\u003Cp>• From the video: “Another exciting peptide is retatrutide. It was developed by Lilly for treating obesity, diabetes, and fatty liver disease . . . What sets retatrutide apart is its triple action approach. Unlike other medications like semaglutide which only targets GLP-1 receptors, retatrutide works on three types of receptors; GIP, GLP-1, and glucagon. This unique combination helps extend feelings of fullness by slowing down the rate at which the stomach empties after meals. It also helps stabilize blood sugar levels by boosting insulin release and converting excess sugar into glucose.”\u003C\u002Fp>\u003Cp>Your “Semaglutide” and “Retatrutide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). &nbsp;Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). &nbsp;No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for these products. &nbsp;Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. &nbsp;You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. &nbsp;It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. &nbsp;Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. &nbsp;Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance &nbsp;\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCurtis Miller\n\nPrime Vitality, Inc. dba Prime Peptides\n\n735 State St., Ste 422\n\nSanta Barbara, CA 93101\n\nUnited States\n\ninfo@primepeptides.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER 695156\nDecember 10, 2024\nDear Curtis Miller:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fprimepeptides.co in October 2024 and has observed that your website offers various products as “peptides” including, “Semaglutide” and “Retatrutide.” We have also reviewed your social media websites at www.facebook.com\u002Fprimepeptidesco, www.instagram.com\u002Fprimepeptidesco, and www.youtube.com\u002F@PrimePeptide. Your social media websites direct consumers to your https:\u002F\u002Fprimepeptides.co website to purchase your products. As described below, your “Semaglutide” and “Retatrutide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nDespite statements on your product labeling marketing your products for “research purposes only” and “not for human consumption or clinical use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\nOn your webpage https:\u002F\u002Fprimepeptides.co\u002Fproducts\u002Fbuy-semaglutide:\n• “Semaglutide reduces cardiovascular events. The SELECT trial showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with preexisting cardiovascular disease and obesity. This included fewer heart attacks and strokes compared to those on placebo.”\n• “Semaglutide improves insulin resistance. A study found that semaglutide helped improve insulin sensitivity in participants, which is crucial for managing and preventing type 2 diabetes. This improvement was seen alongside significant weight loss.”\n• “Mechanism of Action[,] GLP-1 Receptor Activation[,] Appetite Regulation[,] Slowing Gastric Emptying[,] Enhancing Insulin Secretion[,] Reducing Glucagon Production[,] Cardiovascular Benefits[,and] Energy Expenditure and Lipid Metabolism”\nOn your webpage https:\u002F\u002Fprimepeptides.co\u002Fproducts\u002Fbuy-retatrutide:\n• “Retatrutide improves glycemic control. In a study involving patients with type 2 diabetes, retatrutide reduced HbAlc levels by up to 2.02% at 24 weeks. This indicates better blood sugar control, which is crucial for managing diabetes.”\n• “Retatrutide enhances cardiometabolic health. Participants in the trial experienced improvements in cardiometabolic measures, including reductions in waist circumference, blood pressure, and lipid levels. For examples, waist circumference decreased by up to 19.6 cm in some participants.”\n• “Retatrutide reduces liver fat. A 48-week study showed that retatrutide significantly reduced liver fat in obese patients. Those taking 8 mg and 12 mg doses saw liver fat reductions of 23.8% and 25.9% respectively, which is beneficial for liver health.”\nOn your blog post “Top Weight Loss Peptides: Semaglutide, Tirzepatide & More” on your webpage https:\u002F\u002Fprimepeptides.co\u002Fblogs\u002Fpeptides\u002Fweight-loss-peptides:\n• “Top Peptides for Weight Loss: A Quick Guide” with a graphic of a woman with a measuring tape around her waist.\no “Semaglutide . . .Pros: Reduces body weight, controls blood sugar levels, FDA-approved for weight management . . . Statistics: Clinical trials show up to 15% body weight loss”\no “Retatrutide . . . Pros: Targets 3 pathways, most weight loss, treats fatty live . . . Fun Fact: Known as the ‘triple agonist’ for its multi-pathway approach. Statistics: Early trials indicate up to 25% body weight loss.”\n• “Semaglutide can help people who are obese or overweight lose a considerable amount of weight and lower their risk of heart disease, diabetes, and cancer when used in combination with diet and exercise.”\n• “Retatrutide is an emerging peptide developed by Lilly for treating obesity, diabetes, and fatty liver disease. It is common for diabetes medications to be used for weight management, and Retatrutide is a notable example of this trend.”\nOn your social media websites at www.facebook.com\u002Fprimepeptidesco and www.instagram.com\u002Fprimepeptidesco:\n• June 28, 2024 post: “Thanks so much for sharing your experience. We’re so happy to hear you’re loving the benefits! Semaglutide is a GLP-1 receptor agonist known for its significant impact on weight loss, glycemic control, and cardiovascular risk reduction. . . Safe & Effective: Trusted by health professionals worldwide . . . #shareyourexperience #sharingexperience . . . #fitness” with an image of a vial of semaglutide and the text “‘Highly Recommend[,]’ I’ve been using Semaglutide for a few months, and it’s been a game changer. My health and energy levels have improved significantly!”\n• June 23, 2024 post: “Customer Review Highlight! . . . Hearing about your positive experience means everything to us. So glad you’re loving the benefits! . . . Retatrutide is a new medicine that helps control blood sugar and supports weight loss. . . . Safe & Effective: Trusted by health professionals worldwide . . . #shareyourexperience #sharingexperience . . . #fitness” with an image of a woman in active sportswear, a vial of retatrutide and the text “TESTIMONIALS . . . ‘Impressive Weight Loss[,]’ Retatrutide has been impressive for my weight loss journey. I’ve seen significant results in just a few weeks. Highly recommend!”\nOn your YouTube website at www.youtube.com\u002F@PrimePeptide, August 30, 2024 post “Top 5 Peptides for Weight Loss”:\n• From the text below the video: “Top 5 Peptides for Weight Loss │Effective Fat-Burning Peptides . . . Learn how these peptides work, their potential benefits, and how they can help you achieve your weight loss goals. What You’ll Learn: How Semaglutide and Tirzepatide mimic natural hormones to reduce appetite and promote fat loss. The triple-action approach of Retatrutide for maximum weight reduction.”\n• From the video: “GLP-1 peptides also improve your overall health by controlling blood sugar and lowering the risk for heart problems, which are often an issue for people who are overweight. Let’s start by talking about the most popular weight loss peptide, semaglutide. Semaglutide is a medication that can help people with weight-related health issues like type 2 diabetes, high cholesterol, and high blood pressure.”\n• From the video: “Another exciting peptide is retatrutide. It was developed by Lilly for treating obesity, diabetes, and fatty liver disease . . . What sets retatrutide apart is its triple action approach. Unlike other medications like semaglutide which only targets GLP-1 receptors, retatrutide works on three types of receptors; GIP, GLP-1, and glucagon. This unique combination helps extend feelings of fullness by slowing down the rate at which the stomach empties after meals. It also helps stabilize blood sugar levels by boosting insulin release and converting excess sugar into glucose.”\nYour “Semaglutide” and “Retatrutide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Vitality, Inc. dba Prime Peptides","prime-vitality-inc-dba-prime-peptides-695156-12102024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-vitality-inc-dba-prime-peptides-695156-12102024","2026-10-26T08:09:44.176439+00:00","2024-12-17","695156","Curtis Miller","2026-08-19T17:08:03.692+00:00","2024-12-10",6,{"510k":133,"classification":134,"enforcement":135,"event":136,"event_backfill":137,"pma":138,"warning_letter":139},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]